Obsessive-Compulsive Disorder Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant)), by Application (Research Institute, Hospitals & Clinics, Others), by region, and Competition

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2022)

882.50 million

CAGR (2023-2028)

7.60 %

Fastest Growing Segment

SSRI Segment

Largest Market

North America

 

Market Overview

Global Obsessive-Compulsive Disorder Drugs Market has valued at USD 882.50 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.60% through 2028. An anxiety illness known as obsessive-compulsive disorder (OCD) is characterized by irrational and uncontrolled thoughts and concerns that drive a person to engage in repetitive behavior. Obsessive-compulsive disorder is a condition that causes a person to get fixated on a certain idea or fear. Numerous further prospects in the market for OCD medications are anticipated to arise because of recent improvements in therapy, therapies, and innovative treatments as well as in anti-anxiety, antipsychotic, and antidepressant medications. However, the introduction of generic versions of branded medications and the patent expiration of patented ones are two factors anticipated to impede market development over the projection period.

A rising awareness of mental health issues and improved diagnostic criteria have led to more individuals being diagnosed with OCD. As the prevalence of OCD increases, there is a growing demand for effective treatments, driving the market for OCD drugs. Pharmaceutical companies continue to invest in research and development to create more effective and safer drugs for OCD treatment. These advancements result in the introduction of new medications with improved efficacy and reduced side effects. The development of novel treatment approaches, including both pharmacological and non-pharmacological therapies, has expanded the range of options available to individuals with OCD. This, in turn, has driven the market as more tailored treatments become accessible. In many regions, healthcare spending has been on the rise, providing more financial resources for patients to seek and afford treatment for OCD. This increased spending supports the growth of the market. Ongoing research into the neurobiology of OCD may lead to new insights and innovative drug targets, driving the development of new medications and therapies.

Key Market Drivers

Increasing Prevalence of OCD

Increased awareness campaigns, both online and offline, have educated the public and healthcare professionals about the symptoms of OCD. As people become more informed, they are more likely to seek help and receive a diagnosis. Advances in the understanding of OCD have led to more precise diagnostic criteria. This has enabled healthcare providers to identify OCD in individuals who might have previously been misdiagnosed or undiagnosed. Efforts to reduce the stigma associated with mental health conditions have been ongoing. As stigma decreases, individuals are more willing to talk openly about their symptoms and seek treatment without fear of discrimination. In some healthcare settings, routine mental health screenings are becoming more common. This proactive approach can lead to the identification of individuals with OCD who may not have sought help otherwise. OCD often co-occurs with other mental health disorders, such as depression and anxiety. As these comorbid conditions are better recognized and treated, individuals with OCD may also receive a diagnosis and appropriate treatment. Events such as the COVID-19 pandemic have drawn attention to mental health issues, including OCD. The pandemic's impact on mental health has led to increased recognition of OCD symptoms in affected individuals.

Advocacy groups, mental health organizations, and research institutions are working to shed light on the challenges faced by those with OCD. Their efforts raise awareness and promote early diagnosis and intervention. The internet and social media have made it easier for individuals to access information about mental health conditions, including OCD. Online resources and support communities can encourage people to seek help. Shifts in population demographics, including increased urbanization and changes in lifestyle, can contribute to the rise in mental health conditions, including OCD. Modern life is often associated with high levels of stress and anxiety, which can exacerbate OCD symptoms. These stressors may contribute to more individuals seeking help for their symptoms. Research has suggested that both genetic and environmental factors may play a role in the development of OCD. A better understanding of these factors can contribute to early identification. This factor will help in the development of the Global Obsessive-Compulsive Disorder Drugs Market.

Technological Advancements

 Pharmacogenomics involves using genetic information to personalize drug treatment. Advances in this field have allowed healthcare providers to determine which medications are likely to be most effective for a particular individual based on their genetic makeup. This can help optimize OCD drug selection and dosages, improving treatment outcomes. The development of digital therapeutics, including smartphone apps and web-based programs, has provided new avenues for OCD treatment. These digital tools can offer cognitive-behavioral therapy (CBT) and exposure and response prevention (ERP) techniques in an interactive format, allowing individuals to practice coping strategies and self-monitor their progress. The expansion of telemedicine and telepsychiatry services has made it easier for individuals with OCD to access mental health care, including medication management. Remote consultations with psychiatrists and healthcare providers can enhance the availability and convenience of treatment. AI is being used to assist in the diagnosis and treatment of OCD. AI algorithms can help healthcare providers identify patterns and trends in patient data, potentially leading to more accurate diagnoses and treatment recommendations.

Advanced neuroimaging techniques, such as functional magnetic resonance imaging (fMRI), have allowed researchers to gain insights into the brain's activity and structure in individuals with OCD. This has the potential to identify biomarkers and targets for new drug development. Advances in drug delivery systems have led to the development of novel formulations for OCD medications. Controlled-release formulations and transdermal patches can provide more consistent drug levels and improve patient adherence. Precision medicine approaches are becoming increasingly important in the treatment of mental health disorders, including OCD. These approaches aim to tailor treatment plans to individual patient characteristics, such as genetics, biomarkers, and treatment response, to optimize outcomes. Virtual reality (VR) technology is being used to create immersive exposure therapy experiences for individuals with OCD. VR environments can be customized to trigger specific OCD-related obsessions and help patients confront their fears in a controlled setting. Technological devices, such as smart pill dispensers and medication adherence apps, can help individuals with OCD track and manage their medication schedules more effectively. The analysis of large datasets, often referred to as big data analytics, can provide valuable insights into treatment outcomes and patient responses to different medications. This data-driven approach can inform treatment decisions. This factor will pace up the demand of the Global Obsessive-Compulsive Disorder Drugs Market.

Expanded Treatment Options

With a broader range of treatment options, healthcare providers can create more personalized and tailored treatment plans for individuals with OCD. This customization increases the likelihood of successful treatment outcomes, but it may also include the use of medications, hence driving demand for OCD drugs. Many individuals with OCD benefit from a combination of treatments, such as a combination of medication and psychotherapy (e.g., Cognitive-Behavioral Therapy). The availability of multiple treatment modalities allows for more flexible and comprehensive approaches to managing OCD, often including medication as one component. Some individuals with OCD do not respond well to initial treatment attempts. Expanded treatment options provide additional avenues for managing treatment-resistant OCD, which may involve trying different medications or combinations of medications. As more medications are developed and approved for the treatment of OCD, individuals and healthcare providers have more choices beyond the traditional medications. This can include newer drugs with potentially improved efficacy or tolerability profiles.

Different individuals may have varying preferences when it comes to treatment. Some may prefer medication-based approaches, while others may opt for psychotherapy or non-pharmacological interventions. The availability of diverse treatment options allows patients to choose what aligns best with their preferences and values. In severe cases of OCD where symptoms significantly impair daily functioning or pose safety concerns, medications can be an essential part of the treatment plan. The availability of effective medications is crucial for managing such severe cases. For many individuals with OCD, long-term treatment and symptom management are necessary. A variety of medication options and treatment modalities can provide ongoing support and maintenance, ensuring that individuals continue to receive appropriate care. Ongoing research and innovation in the field of OCD treatment have led to the development of new medications and therapeutic approaches. These innovations expand the range of options available to patients and healthcare providers. Effective treatment of OCD can significantly improve an individual's quality of life. As awareness of these treatment options grows, more individuals seek help for their OCD symptoms, leading to increased demand for medications that can aid in their treatment. This factor will accelerate the demand of the Global Obsessive-Compulsive Disorder Drugs Market.


Download Free Sample Report

Key Market Challenges

Comorbid Conditions

Individuals with comorbid conditions often require more complex treatment plans. When OCD is accompanied by other psychiatric disorders like depression, anxiety, or substance abuse, healthcare providers need to consider how these conditions interact and choose medications that can effectively address multiple symptoms. This complexity can lead to challenges in finding the right combination of drugs. Polypharmacy, the use of multiple medications concurrently, may be necessary for individuals with comorbid conditions. This can increase the risk of drug interactions, adverse effects, and medication non-adherence. Healthcare providers must carefully manage medication regimens to optimize treatment outcomes. Comorbid conditions can lead to variations in treatment responses. What works well for one condition may not be as effective for another. Finding medications that are both safe and effective across multiple conditions can be a challenge. Treating individuals with comorbid conditions often involves more frequent healthcare visits, medication management, and therapy sessions. These increased healthcare costs can impact both individuals and healthcare systems, potentially affecting the demand for OCD drugs. The presence of comorbid conditions can complicate the diagnostic process. Symptoms of one condition may mask or mimic those of another, leading to potential misdiagnoses. Accurate diagnosis is essential for tailoring treatment plans. In cases of comorbidity, healthcare providers must prioritize which condition to address first. For example, if a patient has both OCD and a substance use disorder, it may be necessary to treat the substance use disorder before addressing the OCD symptoms effectively.

Cost of Medications

OCD drugs, particularly newer and brand-name medications, can be expensive. High medication costs may create a financial barrier for individuals with OCD, especially those without adequate health insurance or who face high out-of-pocket expenses. As a result, some patients may be unable to afford the medications they need, potentially leading to undertreatment or non-adherence. The extent of insurance coverage for OCD medications can vary widely, depending on the specific drug, the patient's insurance plan, and the healthcare system of their country. In some cases, insurers may require prior authorization, impose high copayments, or place restrictions on certain medications, making them less accessible. While generic versions of some OCD medications may be available at a lower cost, not all drugs have generic equivalents, especially if they are still under patent protection. The lack of generic alternatives can contribute to higher treatment costs. OCD often requires long-term or even lifelong treatment. The cumulative cost of medications over time can become a significant financial burden for patients and their families. High medication costs can also strain healthcare systems and public health budgets, particularly in countries with universal healthcare or government-funded healthcare programs. Expensive medications may lead to increased healthcare expenditures. Some individuals with OCD may discontinue their medications due to cost-related reasons, leading to relapse of symptoms. This can result in increased healthcare utilization and potentially higher overall costs for the healthcare system.

Key Market Trends

Stigma Reduction

 Reduced stigma encourages earlier intervention, which can lead to better treatment outcomes. When individuals seek help at the onset of symptoms, their conditions may be more manageable, potentially reducing the overall duration of treatment and the need for more intensive interventions. Stigma can be a barrier to medication adherence. When individuals are more open about their mental health conditions and receive support from their social networks, they may be more likely to adhere to their treatment plans, including taking prescribed OCD medications consistently. Stigma reduction efforts can lead to increased support for mental health services, including access to psychiatrists, therapists, and medication management. This expansion of services benefits individuals seeking treatment for OCD. When individuals with OCD feel less stigmatized, they may become more empowered to actively participate in their treatment decisions. This can lead to more collaborative and effective treatment plans, including medication choices. Stigma reduction often goes hand in hand with advocacy and support efforts. Patient advocacy groups and mental health organizations play a crucial role in raising awareness, destigmatizing mental health conditions, and advocating for improved access to mental health services and treatments. As stigma diminishes, there is a greater opportunity for the integration of mental health services into primary care settings. This can improve the identification and management of mental health conditions like OCD, potentially leading to more individuals receiving treatment.

Segmental Insights

Type Insights

In 2022, the Global Obsessive-Compulsive Disorder Drugs Market largest share was held by SSRI (Selective Serotonin Reuptake Inhibitors) segment and is predicted to continue expanding over the coming years. SSRIs, a class of antidepressant medications, have demonstrated effectiveness in the treatment of OCD. They are considered a first-line pharmacological treatment option for OCD due to their ability to increase the levels of serotonin in the brain, which is thought to play a role in regulating mood and anxiety. Numerous clinical trials and studies have supported the efficacy of SSRIs in reducing the symptoms of OCD. These trials have shown that a significant percentage of individuals with OCD respond positively to SSRIs, making them a preferred choice for healthcare providers. SSRIs are generally well-tolerated by most patients, with fewer severe side effects compared to some other classes of psychiatric medications. This tolerability makes them a more attractive option for long-term use.

Application Insights

In 2022, the Global Obsessive-Compulsive Disorder Drugs Market largest share was held by Hospitals & Clinics segment in the forecast period and is predicted to continue expanding over the coming years.  Hospitals may be the first point of contact for individuals experiencing severe OCD symptoms. Patients with suspected OCD are evaluated by healthcare professionals, including psychiatrists and psychologists, to confirm the diagnosis and assess the severity of their condition. If a patient is diagnosed with OCD and medication is deemed appropriate for their treatment plan, a healthcare provider, typically a psychiatrist, will prescribe OCD drugs. Selective Serotonin Reuptake Inhibitors (SSRIs) are commonly prescribed medications for OCD. In severe cases of OCD or when the condition is accompanied by other mental health issues or safety concerns, individuals may be admitted to a psychiatric ward or an inpatient facility within the hospital. Here, they receive intensive treatment, including medication management.


Download Free Sample Report

Regional Insights

The North America region dominates the Global Obsessive-Compulsive Disorder Drugs Market in 2022. North America, including the United States and Canada, has a relatively high prevalence of OCD compared to other regions. The estimated prevalence of OCD in the United States is around 1-2% of the population. This high prevalence creates a substantial patient pool in need of treatment, which drives demand for OCD drugs. North America boasts some of the most advanced healthcare infrastructure in the world. This includes well-established healthcare systems, a network of mental health professionals, and a strong pharmaceutical industry. Access to healthcare services, including diagnosis and treatment for OCD, is relatively high in this region. : The United States is a global leader in pharmaceutical research and development. Many pharmaceutical companies headquartered in North America invest in the development of new OCD drugs and therapies. Additionally, academic and research institutions in the region conduct clinical trials and research on OCD treatment, contributing to advancements in the field.

Recent Developments

  • In August 2020, FluGuard (Favipiravir 200 mg) has been introduced by Sun Pharmaceutical Industries Limited in India for the treatment of mild to moderate cases of Covid-19 at a cost-effective price of Rs. 35 a pill. The only oral antiviral medication recognised for use in India to treat individuals with mild to moderate Covid-19 illness is favipiravir.
  • In June2021, the once-daily SOOLANTRA (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea has been made available in the United States by Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. Rosacea inflammation is treated with the help of the prescription drug ivermectin cream, 1%.
  • In June 2022, Brexpiprazole's phase III clinical trial for the management of agitation in patients with Alzheimer's dementia (NCT03548584) has shown encouraging findings, according to Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck). The investigation found that there is a statistically significant difference between brexpiprazole and placebo in the mean change in the Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline to week 12 (p=0.0026). The goal of Trial 331-14-213 (NCT03548584; Trial 213) was to evaluate the effectiveness of two fixed doses of brexpiprazole in the treatment of individuals with agitation associated with Alzheimer's disease. The two dosages were 2 mg/day or 3 mg/day. Patients taking brexpiprazole at doses of 2 mg or 3 mg per day or placebo experienced significantly higher improvements from baseline on the study's primary goal of CMAI (p=0.0026).

Key Market Players

  • Abbott SA
  • Eli Lilly, and Company
  • Viatria Inc.
  • H. LUNDBECK A/S,
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Zydus Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Amneal Pharmaceuticals LLC
  • Teva Pharmaceutical industries Ltd.

By Type

By Application

By Region

By Region
  • SSRI (Selective Serotonin Reuptake Inhibitors)
  • TCA (Tricyclic Antidepressant)
  • Research Institute
  • Hospitals & Clinics
  • others
  • North America
  • Asia-Pacific
  • Europe
  • South America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • Kuwait
  • Bahrain
  • Rest of Middle East

 

Report Scope:

In this report, the Global Obsessive-Compulsive Disorder Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  •     Obsessive-Compulsive Disorder Drugs Market, By Type:

o   SSRI (Selective Serotonin Reuptake Inhibitors)

o   TCA (Tricyclic Antidepressant)

 

  •   Obsessive-Compulsive Disorder Drugs Market, By Application:

 

o   Research Institute

o   Hospitals & Clinics

o   Others

  • Global Obsessive-Compulsive Disorder Drugs Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

 

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Obsessive-Compulsive Disorder Drugs Market.

Available Customizations:

Global Obsessive-Compulsive Disorder Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Obsessive-Compulsive Disorder Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.  Markets Covered

1.2.2.  Years Considered for Study

1.2.3.  Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.    Global Obsessive-Compulsive Disorder Drugs Market Outlook

5.1.  Market Size & Forecast

5.1.1.        By Value

5.2.  Market Share & Forecast

5.2.1.        By Type (SSRI (Selective Serotonin Reuptake Inhibitors), TCA (Tricyclic Antidepressant))

5.2.2.        By Application (Research Institute, Hospitals & Clinics, Others)

5.2.3.        By Region

5.2.4.        By Company (2022)

5.3.  Market Map

6.    Asia Pacific Obsessive-Compulsive Disorder Drugs Market Outlook

6.1.  Market Size & Forecast

6.1.1.        By Value

6.2.  Market Share & Forecast

6.2.1.        By Type

6.2.2.        By Application

6.2.3.        By Country

6.3.  Asia Pacific: Country Analysis

6.3.1.        China Obsessive-Compulsive Disorder Drugs Market Outlook

6.3.1.1.        Market Size & Forecast

6.3.1.1.1.           By Value

6.3.1.2.        Market Share & Forecast

6.3.1.2.1.           By Type

6.3.1.2.2.           By Application

6.3.2.        India Obsessive-Compulsive Disorder Drugs Market Outlook

6.3.2.1.        Market Size & Forecast

6.3.2.1.1.           By Value

6.3.2.2.        Market Share & Forecast

6.3.2.2.1.           By Type

6.3.2.2.2.           By Application

6.3.3.        Australia Obsessive-Compulsive Disorder Drugs Market Outlook

6.3.3.1.        Market Size & Forecast

6.3.3.1.1.           By Value

6.3.3.2.        Market Share & Forecast

6.3.3.2.1.           By Type

6.3.3.2.2.           By Application

6.3.4.        Japan Obsessive-Compulsive Disorder Drugs Market Outlook

6.3.4.1.        Market Size & Forecast

6.3.4.1.1.           By Value

6.3.4.2.        Market Share & Forecast

6.3.4.2.1.           By Type

6.3.4.2.2.           By Application

6.3.5.        South Korea Obsessive-Compulsive Disorder Drugs Market Outlook

6.3.5.1.        Market Size & Forecast

6.3.5.1.1.           By Value

6.3.5.2.        Market Share & Forecast

6.3.5.2.1.           By Type

6.3.5.2.2.           By Application

7.    Europe Obsessive-Compulsive Disorder Drugs Market Outlook

7.1.  Market Size & Forecast

7.1.1.        By Value

7.2.  Market Share & Forecast

7.2.1.        By Type

7.2.2.        By Application

7.2.3.        By Country

7.3.  Europe: Country Analysis

7.3.1.        France Obsessive-Compulsive Disorder Drugs Market Outlook

7.3.1.1.        Market Size & Forecast

7.3.1.1.1.           By Value

7.3.1.2.        Market Share & Forecast

7.3.1.2.1.           By Type

7.3.1.2.2.           By Application

7.3.2.        Germany Obsessive-Compulsive Disorder Drugs Market Outlook

7.3.2.1.        Market Size & Forecast

7.3.2.1.1.           By Value

7.3.2.2.        Market Share & Forecast

7.3.2.2.1.           By Type

7.3.2.2.2.           By Application

7.3.3.        Spain Obsessive-Compulsive Disorder Drugs Market Outlook

7.3.3.1.        Market Size & Forecast

7.3.3.1.1.           By Value

7.3.3.2.        Market Share & Forecast

7.3.3.2.1.           By Type

7.3.3.2.2.           By Application

7.3.4.        Italy Obsessive-Compulsive Disorder Drugs Market Outlook

7.3.4.1.        Market Size & Forecast

7.3.4.1.1.           By Value

7.3.4.2.        Market Share & Forecast

7.3.4.2.1.           By Type

7.3.4.2.2.           By Application

7.3.5.        United Kingdom Obsessive-Compulsive Disorder Drugs Market Outlook

7.3.5.1.        Market Size & Forecast

7.3.5.1.1.           By Value

7.3.5.2.        Market Share & Forecast

7.3.5.2.1.           By Type

7.3.5.2.2.           By Application

8.    North America Obsessive-Compulsive Disorder Drugs Market Outlook

8.1.  Market Size & Forecast

8.1.1.        By Value

8.2.  Market Share & Forecast

8.2.1.        By Type

8.2.2.        By Application

8.2.3.        By Country

8.3.  North America: Country Analysis

8.3.1.        United States Obsessive-Compulsive Disorder Drugs Market Outlook

8.3.1.1.        Market Size & Forecast

8.3.1.1.1.           By Value

8.3.1.2.        Market Share & Forecast

8.3.1.2.1.           By Type

8.3.1.2.2.           By Application

8.3.2.        Mexico Obsessive-Compulsive Disorder Drugs Market Outlook

8.3.2.1.        Market Size & Forecast

8.3.2.1.1.           By Value

8.3.2.2.        Market Share & Forecast

8.3.2.2.1.           By Type

8.3.2.2.2.           By Application

8.3.3.        Canada Obsessive-Compulsive Disorder Drugs Market Outlook

8.3.3.1.        Market Size & Forecast

8.3.3.1.1.           By Value

8.3.3.2.        Market Share & Forecast

8.3.3.2.1.           By Type

8.3.3.2.2.           By Application

9.    South America Obsessive-Compulsive Disorder Drugs Market Outlook

9.1.  Market Size & Forecast

9.1.1.        By Value

9.2.  Market Share & Forecast

9.2.1.        By Type

9.2.2.        By Application

9.2.3.        By Country

9.3.  South America: Country Analysis

9.3.1.        Brazil Obsessive-Compulsive Disorder Drugs Market Outlook

9.3.1.1.        Market Size & Forecast

9.3.1.1.1.           By Value

9.3.1.2.        Market Share & Forecast

9.3.1.2.1.           By Type

9.3.1.2.2.           By Application

9.3.2.        Argentina Obsessive-Compulsive Disorder Drugs Market Outlook

9.3.2.1.        Market Size & Forecast

9.3.2.1.1.           By Value

9.3.2.2.        Market Share & Forecast

9.3.2.2.1.           By Type

9.3.2.2.2.           By Application

9.3.3.        Colombia Obsessive-Compulsive Disorder Drugs Market Outlook

9.3.3.1.        Market Size & Forecast

9.3.3.1.1.           By Value

9.3.3.2.        Market Share & Forecast

9.3.3.2.1.           By Type

9.3.3.2.2.           By Application

10. Middle East and Africa Obsessive-Compulsive Disorder Drugs Market Outlook

10.1.             Market Size & Forecast

10.1.1.     By Value

10.2.             Market Share & Forecast

10.2.1.     By Type

10.2.2.     By Application

10.2.3.     By Country

10.3.             MEA: Country Analysis

10.3.1.     South Africa Obsessive-Compulsive Disorder Drugs Market Outlook

10.3.1.1.     Market Size & Forecast

10.3.1.1.1.         By Value

10.3.1.2.     Market Share & Forecast

10.3.1.2.1.         By Type

10.3.1.2.2.         By Application

10.3.2.     Saudi Arabia Obsessive-Compulsive Disorder Drugs Market Outlook

10.3.2.1.     Market Size & Forecast

10.3.2.1.1.         By Value

10.3.2.2.     Market Share & Forecast

10.3.2.2.1.         By Type

10.3.2.2.2.         By Application

10.3.3.     UAE Obsessive-Compulsive Disorder Drugs Market Outlook

10.3.3.1.     Market Size & Forecast

10.3.3.1.1.         By Value

10.3.3.2.     Market Share & Forecast

10.3.3.2.1.         By Type

10.3.3.2.2.         By Application

11. Market Dynamics

11.1.             Drivers

11.2.             Challenges

12. Market Trends & Developments

12.1.             Recent Developments

12.2.             Product Launches

12.3.             Mergers & Acquisitions

13. Global Obsessive-Compulsive Disorder Drugs Market: SWOT Analysis

14. Porter’s Five Forces Analysis

14.1.             Competition in the Industry

14.2.             Potential of New Entrants

14.3.             Power of Suppliers

14.4.             Power of Customers

14.5.             Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

16.1.   Abbott SA

16.1.1.     Business Overview

16.1.2.     Company Snapshot

16.1.3.     Products & Services

16.1.4.     Financials (In case of listed companies)

16.1.5.     Recent Developments

16.1.6.     SWOT Analysis

16.2.   Eli Lilly, and Company

16.2.1.     Business Overview

16.2.2.     Company Snapshot

16.2.3.     Products & Services

16.2.4.     Financials (In case of listed companies)

16.2.5.     Recent Developments

16.2.6.     SWOT Analysis

16.3.   Viatria Inc.,

16.3.1.     Business Overview

16.3.2.     Company Snapshot

16.3.3.     Products & Services

16.3.4.     Financials (In case of listed companies)

16.3.5.     Recent Developments

16.3.6.     SWOT Analysis

16.4.   H. LUNDBECK A/S

16.4.1.     Business Overview

16.4.2.     Company Snapshot

16.4.3.     Products & Services

16.4.4.     Financials (In case of listed companies)

16.4.5.     Recent Developments

16.4.6.     SWOT Analysis

16.5.   GlaxoSmithKline plc

16.5.1.     Business Overview

16.5.2.     Company Snapshot

16.5.3.     Products & Services

16.5.4.     Financials (In case of listed companies)

16.5.5.     Recent Developments

16.5.6.     SWOT Analysis

16.6.   Pfizer Inc.

16.6.1.     Business Overview

16.6.2.     Company Snapshot

16.6.3.     Products & Services

16.6.4.     Financials (In case of listed companies)

16.6.5.     Recent Developments

16.6.6.     SWOT Analysis

16.7.   Zydus Pharmaceuticals, Inc.

16.7.1.     Business Overview

16.7.2.     Company Snapshot

16.7.3.     Products & Services

16.7.4.     Financials (In case of listed companies)

16.7.5.     Recent Developments

16.7.6.     SWOT Analysis

16.8.   Lupin Pharmaceuticals, Inc.,

16.8.1.     Business Overview

16.8.2.     Company Snapshot

16.8.3.     Products & Services

16.8.4.     Financials (In case of listed companies)

16.8.5.     Recent Developments

16.8.6.     SWOT Analysis

16.9.   Amneal Pharmaceuticals LLC.

16.9.1.     Business Overview

16.9.2.     Company Snapshot

16.9.3.     Products & Services

16.9.4.     Financials (In case of listed companies)

16.9.5.     Recent Developments

16.9.6.     SWOT Analysis

16.10.Teva Pharmaceutical industries Ltd.

16.10.1.  Business Overview

16.10.2.  Company Snapshot

16.10.3.  Products & Services

16.10.4.  Financials (In case of listed companies)

16.10.5.  Recent Developments

16.10.6.  SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Obsessive-Compulsive Disorder Drugs Market was estimated to be USD 882.50 million in 2022.

down-arrow

Eli Lilly and Company, Viatria Inc. are some of the key players operating in the Obsessive-Compulsive Disorder Drugs Market.

down-arrow

Developing and bringing a new drug to market is a lengthy and expensive process

down-arrow

There has been a growing awareness of OCD and related mental health disorders.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Obsessive-Compulsive Disorder Drugs Market to grow with a CAGR of 7.60%

Oct, 2023

Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Obsessive-Compulsive Disorder Drugs Market.

Why Choose Us